Literature DB >> 9633698

Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease.

V Ibáñez1, P Pietrini, G E Alexander, M L Furey, D Teichberg, J C Rajapakse, S I Rapoport, M B Schapiro, B Horwitz.   

Abstract

OBJECTIVE: To determine whether the hypometabolism observed in PET images of patients with Alzheimer's disease (AD) is due entirely to brain atrophy.
BACKGROUND: Reduced brain glucose metabolism in AD patients measured using PET has been reported by numerous authors. Actual glucose metabolic values in AD may be reduced artificially because of brain atrophy, which accentuates the partial volume effect (PVE) on data collected by PET.
METHODS: Using segmented MR images, we corrected regional cerebral metabolic rates for glucose for PVEs to evaluate the effect of atrophy on uncorrected values for brain metabolism in AD patients and healthy control subjects.
RESULTS: Global glucose metabolism was reduced significantly before and after correction in AD patients compared with controls. Before PVE correction, glucose metabolic values in patients were lower than in control subjects in the inferior parietal, frontal, and lateral temporal cortex; in the posterior cingulate; and in the precuneus. These reductions remained significantly lower after PVE correction, although in the posterior cingulate the difference in metabolism between AD patients and control subjects lessened. Regional glucose metabolism of these areas with PVE correction was lower in moderately-severely demented patients than in mildly demented patients.
CONCLUSION: Reduced glucose metabolism measured by PET in AD is not simply an artifact due to an increase in CSF space induced by atrophy, but reflects a true metabolic reduction per gram of tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633698     DOI: 10.1212/wnl.50.6.1585

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  89 in total

1.  Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease.

Authors:  S I Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  The utility of (11)C-arachidonate PET to study in vivo dopaminergic neurotransmission in humans.

Authors:  Madhav Thambisetty; Kathy A Gallardo; Jeih-San Liow; Lori L Beason-Held; John C Umhau; Abesh K Bhattacharjee; Margaret Der; Peter Herscovitch; Judith L Rapoport; Stanley I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

3.  Age-related metabolic profiles in cognitively healthy elders: results from a voxel-based [18F]fluorodeoxyglucose-positron-emission tomography study with partial volume effects correction.

Authors:  P K Curiati; J H Tamashiro-Duran; F L S Duran; C A Buchpiguel; P Squarzoni; D C Romano; H Vallada; P R Menezes; M Scazufca; G F Busatto; T C T F Alves
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-27       Impact factor: 3.825

4.  Characterizing Alzheimer's disease using a hypometabolic convergence index.

Authors:  Kewei Chen; Napatkamon Ayutyanont; Jessica B S Langbaum; Adam S Fleisher; Cole Reschke; Wendy Lee; Xiaofen Liu; Dan Bandy; Gene E Alexander; Paul M Thompson; Leslie Shaw; John Q Trojanowski; Clifford R Jack; Susan M Landau; Norman L Foster; Danielle J Harvey; Michael W Weiner; Robert A Koeppe; William J Jagust; Eric M Reiman
Journal:  Neuroimage       Date:  2011-01-27       Impact factor: 6.556

5.  Distribution of cortical benzodiazepine receptor binding in right-handed healthy humans: a voxel-based statistical analysis of iodine 123 iomazenil SPECT with partial volume correction.

Authors:  H Kato; E Shimosegawa; K Isohashi; N Kimura; H Kazui; J Hatazawa
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-08       Impact factor: 3.825

Review 6.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

7.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

Review 8.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

9.  Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain.

Authors:  Winnie S Liang; Travis Dunckley; Thomas G Beach; Andrew Grover; Diego Mastroeni; Douglas G Walker; Richard J Caselli; Walter A Kukull; Daniel McKeel; John C Morris; Christine Hulette; Donald Schmechel; Gene E Alexander; Eric M Reiman; Joseph Rogers; Dietrich A Stephan
Journal:  Physiol Genomics       Date:  2006-10-31       Impact factor: 3.107

10.  Brain FDG PET study of normal aging in Japanese: effect of atrophy correction.

Authors:  Daisuke Yanase; Ichiro Matsunari; Kazuyoshi Yajima; Weiping Chen; Akihiko Fujikawa; Shintaro Nishimura; Hiroshi Matsuda; Masahito Yamada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.